2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷) : 2022-04-15±³À°ÀÏÀÚ : 2022-04-15
±³À°Àå¼Ò : °æÁÖ HICO
±³À°ÁÖÁ¦ :
2022 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ & ACC(American College of Cardiology) Asia 2022 (¿Â,¿ÀÇÁ¶óÀÎ)(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258
À̸ÞÀÏ :
herz8@circulation.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í ±³¼ö ¹× °³¿øÀÇ: 80,000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ: 40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-15 Rm.300C 08:40~08:50 Case: COVID and Myocarditis In Cheol Kim(Keimyung Univ. Korea)
±³À°½Ã°£ 04-15 Rm.300C 08:50~09:00 Case: Inflammatory Disease Affecting the Heart Leslie Cooper(Mayo Clinic USA)
±³À°½Ã°£ 04-15 Rm.300C 09:00~09:10 Case: Cancer Treatment and Myocarditis Ana Barac(MedStar Heart and Vascular Institute USA)
Åä·Ð 04-15 Rm.300C 09:10~09:25 Discussion ()
ÈÞ½Ä 04-15 09:25~09:35 Break ()
±³À°½Ã°£ 04-15 Rm.103 09:35~09:45 Nondevice Therapies and SCD Prevention Jong-Il Choi(Korea Univ. Korea)
±³À°½Ã°£ 04-15 Rm.103 09:45~09:55 ICDs in NICM: Who and When Fred Kusumoto(Mayo Clinic USA)
±³À°½Ã°£ 04-15 Rm.103 09:55~10:05 ICDs in Channelopathies and HCM Matthew Martinez(NYU Langone Health USA)
Åä·Ð 04-15 Rm.103 10:05~10:20 Discussion ()
ÈÞ½Ä 04-15 10:20~10:30 Break ()
±³À°½Ã°£ 04-15 Rm.203 10:30~10:45 Optimal Management and Monitoring during ECMO in Ptients with Cardiogenic Shock Á¤Àç½Â(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.203 10:45~11:00 Optimal ECMO Weaning and Post-ECMO Care in Patients with Cardiogenic Shock ¾çÁ¤ÈÆ(¼º±Õ°üÀÇ´ë)
Åä·Ð 04-15 Rm.203 11:00~11:15 Discussion ()
ÈÞ½Ä 04-15 11:15~11:25 Break ()
±³À°½Ã°£ 04-15 Rm.205 11:25~11:37 Arterial Switch Operation °ûÀç°Ç(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.205 11:37~11:49 Ross Procedure ¹Úõ¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.205 11:49~12:01 Fontan Operation ¾çÁöÇõ(¼º±Õ°üÀÇ´ë)
Åä·Ð 04-15 Rm.205 12:01~12:10 Discussion ()
ÈÞ½Ä 04-15 12:10~12:20 Break ()
±³À°½Ã°£ 04-15 Rm.102 12:20~12:40 Early Bird of High Intensity Statin to close the gap betwwen theory and practice in ACS patients ¹æ´ö¿ø(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.102 12:40~13:00 When and why combination therapy is needed for dyslipidemia patients? as the next option of maximum tolerable mono statin therapy. ¼ÕÁ¤¿ì(¿¬¼¼¿øÁÖÀÇ´ë)
ÈÞ½Ä 04-15 13:00~13:10 Break ()
±³À°½Ã°£ 04-15 Rm.102 13:10~13:30 Expanding Role of Entresto for HF with below normal EF Gregg C. Fonarow(Ronald Reagan UCLA Medical Center USA)
±³À°½Ã°£ 04-15 Rm.102 13:30~13:50 Evolving role of Entresto as first choice for your HF patient Hyun-Jai Cho(Seoul National Univ. Korea)
ÈÞ½Ä 04-15 13:50~14:00 Break ()
±³À°½Ã°£ 04-15 Rm.105 14:00~14:12 How to decide rhythm or rate control strategy ¹ÚÁ¾¼º(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.105 14:12~14:24 Current results of radiofrequency or Cryo ablation for AF °íÁ¡¼®(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.105 14:24~14:36 New technologies for AF detection and management À¯ÈñÅÂ(¿¬¼¼ÀÇ´ë)
Åä·Ð 04-15 Rm.105 14:36~14:45 Discussion ()
ÈÞ½Ä 04-15 14:45~14:55 Break ()
±³À°½Ã°£ 04-15 Rm.105 14:55~15:07 How to Find Culprit Lesion and Manage Non-Culprit Lesion: Imaging and Physiology ±èÇö±¹(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.105 15:07~15:19 How to Overcome Coronary Thrombosis During Primary PCI À±¿µÁø(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.105 15:19~15:31 Which Is the First Strategy in AMI with Cardiogenic Shock: VA-ECMO or PCI? Àå¿ìÁø(ÀÌÈÀÇ´ë)
Åä·Ð 04-15 Rm.105 15:31~15:40 Discussion ()
ÈÞ½Ä 04-15 15:40~15:50 Break ()
±³À°½Ã°£ 04-15 Rm.205 15:50~16:10 Murine and Rodent Model À̽ÂÁØ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.205 16:10~16:30 Pig Model ÀÓ°æ¼·(Çѱ¹»ý¸í°øÇבּ¸¿ø)
±³À°½Ã°£ 04-15 Rm.205 16:30~16:50 In Vitro Model: Cell Line and Patient Specific iPSC-derived Cardiovascular Cell ¾çÇѸð(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-15 Rm.205 16:50~17:10 Electrophysiology and Echocardiography Evaluation in Animal Model °íÅÂÈñ(°í·ÁÀÇ´ë)
Åä·Ð 04-15 Rm.205 17:10~17:20 Discussion ()